Biotech Earnings Preview

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

It's Fools' favorite time of the year: earnings season.

In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss a few biotechs that will release first quarter earnings shortly.

Gilead Sciences (NASDAQ: GILD  ) is scheduled to release earnings on Tuesday after the market closes. We know sales of its new hepatitis C drug Sovaldi will be good, but just how good remains to be seen. Investors should also listen for what management says about sustainability of sales ahead of the approval of a combination product under review with the FDA.

Sales of Arena Pharmaceuticals' (NASDAQ: ARNA  ) obesity drug Belviq won't be Sovaldi-good. Not even close. But sales of Belviq might pass sales of VIVUS' (NASDAQ: VVUS  ) Qsymia, which would be a good start to reaching its full potential. Neither VIVUS nor Arena have announced the date they plan to report first quarter earnings, but investors should get the Belviq sales figure when its partner Eisai reports on May 13 if Arena hasn't reported yet.

For Biogen Idec (NASDAQ: BIIB  ) , which will report on Wednesday, the key drug to watch is its oral multiple sclerosis drug Tecfidera. Investors should not only be concerned with how the launch is going, but whether sales of Tecfidera is cutting into sales of Biogen's other multiple sclerosis drugs, Avonex and Tysabri.

Watch the video below for more thoughts on the three companies.

Looking for megagrowth?
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2923194, ~/Articles/ArticleHandler.aspx, 9/5/2015 6:32:33 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 3:59 PM
ARNA $2.74 Down -0.01 -0.36%
Arena Pharmaceutic… CAPS Rating: **
BIIB $302.26 Up +0.63 +0.21%
Biogen Idec CAPS Rating: ****
GILD $102.06 Up +0.15 +0.15%
Gilead Sciences CAPS Rating: *****
VVUS $1.19 Down -0.07 -5.56%
VIVUS, Inc. CAPS Rating: **